Point of care performance of the improved BIOCREDIT Ag Pf/Pv (pLDH/pLDH) rapid diagnostic test: a cross-sectional study at a health center setting in Ethiopia Authors: Eshetu Molla, Eyob Fekadu, Zemed Biyazen, Fikregabrail Aberra Kassa, Melat Gebremedhin Teklewold, Tedros Nigussie, Mihret Ebabu, Mequanint Mande, Muluye Shimeles, Daniel Legese Achalu, Solomon Feleke, Mamud Umer, Derese Bekele Daba, Anneleye Fantahun, Miraf Mesfin, Adamu Bayissa, Sampa Pal, Dagmawi Hailu Yemane, Emily Gerth-Guyette, Stephan Duparc, Gonzalo J Domingo, Endalamaw Gadisa Published: 2026 ABSTRACT AbstractBackgroundIn Ethiopia, co-endemic Plasmodium falciparum and P. vivax require species-specific point-of-care diagnosis and treatment. Following pfhrp2/3 deletions, Ethiopia adopted non-HRP2/3 rapid diagnostic tests (RDTs). This study evaluated the point-of-care diagnostic performance of the improved BIOCREDIT Ag Pf/Pv (pLDH/pLDH) RDT compared to microscopy (comparator), using the 18S rRNA-based qPCR as the reference standard.MethodsThis prospective cross-sectional study was nested within an operational feasibility study of radical cure for P. vivax with tafenoquine or primaquine after semi-quantitative G6PD testing in Ethiopia. Conducted from December 2024 to September 2025, it took place at Village 8/9 and Beto Health Centers in Gambella and South Ethiopia regions, respectively. Self-reporting clinical malaria cases (n = 1200) were enrolled, with 846 from Village 8/9 and 354 from Beto. Approximately 150 µL of capillary blood was collected from each participant for point-of-care RDTs (5 µL), thick and thin smear microscopy (7 µL), and dried blood spots (140 µL) for 18S rRNA qPCR. Diagnostic performance was evaluated through sensitivity, specificity, kappa agreement (κ), and case detection comparisons across RDT, qPCR, and microscopy. Associations between parasite density and detectability, as well as the geographic distribution of species, age, and sex, were assessed.ResultsUsing 18S qPCR, malaria prevalence rate was 40.6% (487/1,200): 63.0% P. falciparum, 29.6% P. vivax, and 7.4% mixed infections. P. falciparum predominated in Gambella (68.5%, 217/317) vis-à-vis South Ethiopia (52.9%, 90/170), whereas P. vivax was more common in South Ethiopia (37.6%, 64/170) vis-à-vis Gambella (25.2%, 80/317). The RDT showed higher sensitivity for qPCR-confirmed Plasmodium infections (89.7%) than routine microscopy (59.8%), with comparable specificities (97.2% versus 96.5%). Species-specific sensitivities were 87.9% for P. falciparum, 86.7% for P. vivax, and 50.0% for mixed infections. Agreement with qPCR was strong for RDT (κ = 0.92) and moderate for microscopy (κ = 0.79). Overall diagnostic accuracy was excellent (AUC ≥ 0.92 for both species). RDT sensitivity declined at low parasite densities but reached 100% at ≥ 5,000 copies/µL for both species.ConclusionsThe RDT demonstrated strong accuracy for point-of-care, species-specific malaria diagnosis in Ethiopian primary healthcare. Its high sensitivity, particularly for moderate- to high-density infections, supports routine clinical use following Ethiopia’s shift to non-HRP2 RDTs.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12936-026-05994-x.Keyword: Malaria diagnosis, Plasmodium falciparum, Plasmodium vivax, Lactate dehydrogenase, Point-of-care setting, Ethiopia Background Most parts of Ethiopia are malarious, with an estimated 52% of the population at risk [1]. Plasmodium falciparum (P. falciparum) and P. vivax co-exist in all malarious areas at different levels of endemicity. In 2024, there were 7.3 million confirmed malaria cases, with four regions (Oromia, Amhara, Southwest, and South Ethiopia) accounting for 81% of the reported cases [2], underlining the public health challenge posed by malaria. Ethiopia's National Strategic Plan for Malaria Prevention, Control, and Elimination (2021–2025) requires species-specific parasitological confirmation of all clinical suspects using light microscopy or antigen-detecting RDTs, to ensure proper and adequate management [1]. Microscopy, the gold standard for routine diagnostics in Ethiopia, depends on the availability of experienced personnel, reagents, and laboratory infrastructure, limiting access in rural areas [3]. However, it also suffers from low sensitivity at low parasite densities (often missing infections below 50–100 parasites/μL), poor to moderate capacity of laboratories, disrupted electricity, challenges in maintaining consistent quality control due to variability in training and equipment, being time-consuming and laborious (requiring examination of 100 or more microscopic fields per slide), and potential for misidentification of Plasmodium species, especially in mixed infections where one species may be underreported [4–6]. Some evidence indicated that pLDH-based RDTs can detect infections missed by microscopy, especially low-density parasitemia, which is common in Ethiopia [7, 8]. The early-2000s introduction of RDTs, particularly the HRP2-based, enabled decentralized testing, reduced presumptive treatment, and contributed to an estimated 50–86% reduction in malaria mortality between 2000 and 2019 [9]. The widespread pfhrp2/3 gene deletions (pfhrp2: ~ 22%; pfhrp3: ~ 69%; exceeding WHO’s 5% threshold for policy shift in multiple regions) threatened the 2030 elimination targets, and Ethiopia responded by adopting non-HRP2-based RDTs (pLDH-targeting) in 2023–2024 [2, 10]. The pLDH-based RDTs detect the enzyme lactate dehydrogenase produced [11, 12] reducing the false-positivity rates associated with the persistence of HRP2 antigenemia [11, 13]. Also, the pLDH-based platforms offer an advantage for more sensitive detection of P. vivax in P. falciparum and P. vivax co-endemic setting like Ethiopia. Among these newer non-HRP2 assays, the BIOCREDIT Ag Pf/Pv (pLDH/pLDH) RDT is WHO-prequalified (PQDx 13,194-160-00) and in routine use in the Ethiopian care system. This improved third-generation pLDH-based RDT has demonstrated enhanced analytical sensitivity compared to earlier pLDH-based assays [7]. Therefore, this study assessed the routine point-of-care diagnostic performance of the BIOCREDIT Ag Pf/Pv (pLDH/pLDH) RDT, using facility microscopy as a comparator and 18S rRNA qPCR as the reference standard. Methods Study sites, period, and design The study was conducted at two health centers (HCs), Village 8/9 and Beto, in Gambella and South Ethiopia regional states, respectively. The HCs were selected to represent co-endemic transmission settings; Gambella is characterized by high transmission predominantly of P. falciparum (annual parasite incidence, API, of ≥ 50 cases per 1,000 population), while South Ethiopia has moderate transmission of both P. falciparum and P. vivax (API between 10 and 50) [1, 14]. This health facility-based prospective cross-sectional study was conducted from December 2024 to September 2025. Study population and diagnostic procedures The study included self-presenting individuals aged ≥ 6 months of both sexes who presented to the HCs with signs and symptoms suggestive of malaria, including fever (axillary temperature ≥ 37.5 °C), or history of fever in the preceding 48 h, accompanied by signs such as chills, headache, myalgia, nausea, and provision of informed written consent (or assent for children). As shown in the study flow diagram (Fig. 1), all participants who met these criteria and provided consent were consecutively enrolled without subsequent exclusions. Flow diagram describing participant enrollment and diagnostic test results. All 1,200 participants were tested by BIOCREDIT Ag Pf/Pv (pLDH/pLDH) RDT, microscopy (comparator), and qPCR (reference standard). TN True negative, FN False negative, TP True positive, FP False positive Sample size determination Sample size was estimated at 1,200 participants using a paired-sample McNemar test. This calculation was designed to achieve at least 80% power to detect a 10% difference in sensitivity between the BIOCREDIT Ag Pf/Pv (pLDH/pLDH) RDT (assumed sensitivity of 95%) and microscopy for P. falciparum and P. vivax. Based on an expected 12% prevalence of P. falciparum and 5% prevalence of P. vivax, this corresponds to approximately 144 and 60 positive cases, respectively. The calculations assumed uncorrelated test results (a conservative approach) and were performed using PASS 2022 (version 22.0.2). Sample and data collection and processing Capillary blood samples (~ 150 µL) were collected from each participant via a single finger prick following standard aseptic procedures. Samples were used immediately at the health facility for the BIOCREDIT Ag Pf/Pv (pLDH/pLDH) RDT (5 µL) and microscopy (7 µL; 2 µL for thin smear and 5 µL for thick smear). Three dried blood spots (DBS; 140 µL) were prepared on Whatman 903 Paper Protein Saver Cards (76 × 108 mm; Cytiva, USA, Lot 7,317,324) for subsequent 18S rRNA-based quantitative PCR (qPCR) analysis. DBS were air-dried for 4 h at room temperature, stored in individual sealed plastic bags with desiccant, and transported to the Armauer Hansen Research Institute (AHRI) laboratory in Addis Ababa for molecular assay. Socio-demographic data, including study sites, age, and sex, were collected from participants using a pretested data collection form. Microscopy and BIOCREDIT Ag Pf/Pv (pLDH/pLDH) RDT Microscopic examination was performed on-site at the health facilities. Thick and thin blood smears were prepared, air-dried, and stained with 10% Giemsa for 10 min. Slides were examined under an oil immersion objective; 100 fields were examined to declare negative. Thick smears were used for parasite detection, while thin smears aided in species identification. The laboratory personnel performed the BIOCREDIT Ag Pf/Pv (pLDH/pLDH) RDT according to the manufacturer’s instructions at the routine point-of-care setting (RapiGEN Inc., Suwon-si, Gyeonggi-do, 16,648, Republic of Korea; Lot H016C007D). Briefly, about 5 µL of capillary blood was added to the sample well using a micropipette, followed by 3 drops of assay buffer. Results were read after 20–35 min. Negative readings at 25 min were read again at 35 min. Both the RDT and microscopy were performed by the routine facility laboratory personnel who are normally responsible for malaria diagnostic testing at the two HCs. Prior to study initiation, these personnel received refresher training on RDT procedures, smear preparation, staining, and parasite identification, conducted at the start of the study period. Following this initiation training, the laboratory personnel conducted all diagnostic procedures independently and under routine working conditions, with no additional supervision from the study team beyond the standard quality assurance mechanisms already in place at the facilities. DNA extraction and 18S qPCR assay Whole-genome DNA was extracted from the DBS using the DNeasy Blood & Tissue Kit (Qiagen, Germany, Cat No 69506) following the manufacturer’s protocol. A 6 mm punch was soaked in 180 µL buffer ATL and 20 µL proteinase K (20 mg/mL), followed by binding to a DNeasy Mini spin column. After sequential washes with buffers 500 µL AW1 and 500 µL AW2, DNA was eluted in 200 µL buffer AE. The DNA eluate was stored at -20 ºC until the qPCR assay. The qPCR was performed using a TaqMan-based (Thermo Fisher Scientific, Lithuania, Lot 3,015,520) multiplex assay targeting the 18S rRNA gene to detect and quantify P. falciparum and P. vivax. Each run included known positive and negative controls. The reaction run in 20 µL final volume contained 5 µL genomic DNA (5 to 105 ng/µL), 10 µL of 2 × TaqMan Fast Advanced Master Mix (Applied Biosystems, #4,444,964), Pf18S primers at 300 nM and probe at 111 nM, Pv18S primers at 200 nM and probe at 110 nM, and nuclease-free water. Plasmodium density was quantified in 18S gene copies/µL from standard curves generated with serial plasmid dilutions (10^7–10^3 parasites/µL), with cycle threshold (CT) values ≤ 37.69 for P. falciparum and ≤ 37.18 for P. vivax considered positives (based on the mean CT values of 10^3 dilution). Based on the estimated 6 copies of 18S rRNA per P. falciparum genome [15], 1 copy/μL of P. falciparum gene is equivalent to 0.17 parasites/μL [16]. Similarly, one copy of plasmid DNA corresponds to 0.127 parasite/μL for P. vivax [17]. Details of the primer and probe sequences and quantification curves are provided in the Supplementary Fig. 1 and Supplementary Tables 1–3. Data analysis Data was managed using REDCap 13.10.1 (Vanderbilt University, USA) and analyzed using R version 4.5.1 (the R Foundation for Statistical Computing Platform). Diagnostic performance metrics, including sensitivity, specificity, and positive and negative predictive values, were calculated against qPCR. The incremental benefit was assessed as the number and proportion of infections detected by BIOCREDIT Ag Pf/Pv (pLDH/pLDH) RDT but missed by microscopy, and agreement between methods was evaluated using the Kappa statistic. Associations between parasite density and species distribution, and detectability were evaluated. Receiver operating characteristic (ROC) curves were also generated to evaluate the overall diagnostic accuracy of the BIOCREDIT Ag Pf/Pv (pLDH/pLDH) RDT using the area under the curve. Associations between sensitivity and parasite density (in terms of 18S rRNA gene copy numbers) were assessed using logistic regression and correlation (e.g., Spearman’s rho), while species distribution was stratified by region, age groups, and sex using chi-square tests. Results Participant characteristics We enrolled 1200 participants (Fig. 1). Overall, males comprised 52.4% (n = 629), the mean age was 23.0 years (SD 27.1), and the majority (n = 729, 60.8%) were in the 15–49 years age group (Table 1). Table 1Socio-demographic characteristics of the study participants (N = 1,200)CharacteristicOverall (N = 1,200)1Gambella (n = 846)1South Ethiopia (n = 354)1Age (years)1, mean (SD)23.0 (27.1)24.1 (30.9)20.4 (14.0)Age group, n (%) < 5 years94 (7.8%)51 (6.0%)43 (12.1%) 5–14 years303 (25.3%)215 (25.4%)88 (24.9%) 15–49 years729 (60.8%)522 (61.7%)207 (58.5%) ≥ 50 years74 (6.2%)58 (6.9%)16 (4.5%)Sex, n (%) Female571 (47.6%)419 (49.5%)152 (42.9%) Male629 (52.4%)427 (50.5%)202 (57.1%)District, n (%) Abobo846 (70.5%)846 (100.0%)NA Beto328 (27.3%)NA328 (92.7%) Udt26 (2.2%)NA26 (7.3%)1Mean (SD); n (%)Any Plasmodium: Both P. falciparum and P. vivax Socio-demographic characteristics of the study participants (N = 1,200) 1Mean (SD); n (%) Any Plasmodium: Both P. falciparum and P. vivax Performance of BIOCREDIT Ag Pf/Pv (pLDH/pLDH) RDT in detecting Plasmodium infection The BIOCREDIT Ag Pf/Pv (pLDH/pLDH) RDT demonstrated superior sensitivity compared to facility microscopists for species specific diagnosis; P. falciparum (87.9% vis a vis 55.0%), P. vivax (86.7% vis a vis 60.0%), and mixed infections (50.0% vis a vis 44.4%). Its specificity for any Plasmodium (97.2%, 95% CI 96.0–98.0) was comparable to the facility microscopy (96.5%, 95% CI 95.1–97.6). For any Plasmodium (n = 487 qPCR positives), the BIOCREDIT Ag Pf/Pv (pLDH/pLDH) RDT detected 29 additional cases missed by facility microscopy, representing RDT-positive cases confirmed by qPCR that were negative by routine facility microscopy. Overall agreement of the BIOCREDIT Ag Pf/Pv (pLDH/pLDH) RDT with qPCR (sensitivity for any Plasmodium) was 89.7% (κ = 0.92); while the agreement for facility microscopists with qPCR was 59.8% (κ = 0.79). The BIOCREDIT Ag Pf/Pv (pLDH/pLDH) RDT demonstrated κ values of 0.91 for P. falciparum and 0.89 for P. vivax. While facility microscopy showed only moderate agreement for P. falciparum (κ = 0.58) and substantial agreement for P. vivax (κ = 0.65). For mixed infections, RDT maintained a moderate agreement (κ = 0.62), relatively outperforming microscopy (κ = 0.52). For any Plasmodium infection, the PPV was 95.4%, and the NPV was 93.4%, with an accuracy of 94.2% (Table 2). RDT also achieved excellent discriminatory performance, with AUCs of 0.92 (95% CI: 0.90–0.94) for P. falciparum and 0.93 (95% CI: 0.91–0.96) for P. vivax, outperforming microscopy, which showed AUCs of 0.77 (95% CI: 0.75–0.80) and 0.91 (95% CI: 0.89–0.94), respectively (Supplementary Fig. 2). The 2 × 2 contingency table for the microscopy and qPCR is presented in Supplementary Table 4. Table 2Diagnostic performance of the BIOCREDIT Ag Pf/Pv (pLDH/pLDH) RDT and facility microscopist against 18S rRNA qPCR as the reference standard (N = 1,200)SpeciesTestSensitivity % (95% CI)Specificity % (95% CI)PPV %NPV %Accuracy %κAny PlasmodiumRDT89.7 (84.8–93.2)97.2 (95.9–98.1)95.493.494.20.92Facility microscopy59.8 (52.8–66.5)96.5 (95.1–97.6)92.180.582.30.79P. falciparumRDT87.9 (81.2–92.4)97.7 (96.6–98.5)91.396.395.10.91Facility microscopy55.0 (46.5–63.2)97.5 (96.3–98.4)85.789.888.40.58P. vivaxRDT86.7 (75.8–93.1)99.7 (99.2–99.9)91.498.497.60.89Facility microscopy60.0 (47.0–71.5)98.5 (97.5–99.2)80.696.294.80.65Mixed infectionsRDT50.0 (32.9–67.1)99.8 (99.3–99.9)90.098.598.30.62Facility microscopy44.4 (27.9–61.9)99.4 (98.8–99.7)69.698.397.80.52Summary metrics (any Plasmodium)RDT incremental detections vs microscopy (n)29-----Overall % agreement (RDT)89.7%-----Overall % agreement (microscopy)59.8%-----RDT: BIOCREDIT Ag Pf/Pv (pLDH/pLDH) rapid diagnostic test; PPV: Positive predictive value; NPV: Negative predictive value; Kappa agreement: κ; RDT incremental detections vs microscopy: The number of additional Plasmodium infections detected by RDT that were missed by facility microscopy, as confirmed by qPCR Diagnostic performance of the BIOCREDIT Ag Pf/Pv (pLDH/pLDH) RDT and facility microscopist against 18S rRNA qPCR as the reference standard (N = 1,200) RDT: BIOCREDIT Ag Pf/Pv (pLDH/pLDH) rapid diagnostic test; PPV: Positive predictive value; NPV: Negative predictive value; Kappa agreement: κ; RDT incremental detections vs microscopy: The number of additional Plasmodium infections detected by RDT that were missed by facility microscopy, as confirmed by qPCR Parasite density and detectability by RDT and microscopy The median and mean parasite densities for P. falciparum qPCR positive samples (n = 343) were 364 (interquartile range, IQR: 18–10,456) and 27,781 copies/µL, respectively. The median and mean parasite densities for P. vivax qPCR positive samples (n = 180) were 173 (IQR: 2–6,767) and 9,114 copies/µL, respectively. Overall, 42% of P. falciparum and 37% of P. vivax infections were low-density (< 1,000 copies/µL) (Supplementary Table 5). The sensitivity of both microscopy and the BIOCREDIT Ag Pf/Pv (pLDH/pLDH) RDT increased with parasite density. For P. falciparum, RDT-negative samples clustered at a low median of 18S gene copies. The RDT demonstrated 67.4% (95% CI 59.1–74.9%; n = 144) for low-density infections (median: 29 copies/µL). Sensitivity increased to 100% (95% CI: (93.3–100.0%; n = 53) at intermediate parasite densities (1,000–4,999 copies/µL) and remained 100% (95% CI: 97.5–100.0%; n = 146) at high densities (≥ 5,000 copies/µL). Facility microscopy showed a similar trend, increasing from 78.5% (95% CI: 71.2–84.6%; n = 144) at < 1,000 copies/µL to 96.6% (88.3–99.6%; n = 53) at 1,000–4,999 copies/µL and 99.2% (95.7–100%; n = 146) at ≥ 5,000 copies/µL, but relatively lower performance at intermediate densities (Fig. 2; Supplementary Table 6). Sensitivity of the BIOCREDIT Ag Pf/Pv (pLDH/pLDH) RDT and microscopy by parasite density as measured by copies/µL of the 18S rRNA qPCR, P. falciparum (n = 343) and P. vivax (n = 180) A comparable trend was observed for P. vivax, where RDT-negative samples appeared at the lowest qPCR-derived densities. The RDT sensitivity increased from 68.2% (95% CI: 55.6–79.1%; n = 66) at < 1,000 copies/µL to 98.4% (89.7–100%; n = 32) at 1,000–4,999 copies/µL and reached 100% (95% CI: 95.6–100.0%; n = 82) at ≥ 5,000 copies/µL. Facility microscopy again showed relatively stronger performance at low densities, at 57 copies/µL, the sensitivity was 72.0% (CI: 60.9–81.3; n = 66), which increased to 90.6% (75–98%; n = 32) at 1,000–4,999 copies/µL and 100% (95% CI: 91.6–100%; n = 82) at 5,538 copies/µL (Fig. 2; Supplementary Table 6). Species distribution Of the 487 Plasmodium infections (317 from Gambella and 170 from south Ethiopia) detected by qPCR, P. falciparum accounted for 63.0% (n = 307), followed by P. vivax (29.6%, n = 144), and mixed infections (7.4%, n = 36). The distribution of species varied significantly by region (Fisher's exact test, p = 0.003). Among the total positive cases in each region, P. falciparum accounted for 68.5% (n = 217) in Gambella compared with South Ethiopia (52.9%, n = 90), whereas P. vivax was more common in South Ethiopia (37.6%, n = 64) than in Gambella (25.2%, n = 80) (Table 3). Table 3Distribution of Plasmodium species by region, age group, and sex among participants tested by qPCR in Ethiopia (N = 487)VariableCategoryP. falciparumP. vivaxMixedTotal, n (%, n/N)RegionGambella217 (68.5%)80 (25.2%)20 (6.3%)317 (65.1%, 317/487)South Ethiopia90 (52.9%)64 (37.6%)16 (9.4%)170 (34.9%, 170/487)Total307 (63.0%)144 (29.6%)36 (7.4%)p-value0.003Age group < 5 years19 (3.9%)17 (3.5%)5 (1.0%)41 (8.4%)5–14 years96 (19.7%)51 (10.5%)11 (2.3%)158 (32.4%)15–49 years173 (35.5%)74 (15.2%)19 (3.9%)266 (54.6%) ≥ 50 years19 (3.9%)2 (0.4%)1 (0.2%)22 (4.5%)Total307 (63.0%)144 (29.6%)36 (7.4%)487 (100%)p-value0.078SexMale183 (37.6%)80 (16.4%)18 (3.7%)281 (57.7%)Female124 (25.5%)64 (13.1%)18 (3.7%)206 (42.3%)Total307 (63.0%)144 (29.6%)36 (7.4%)487 (100%)p-value0.448 Distribution of Plasmodium species by region, age group, and sex among participants tested by qPCR in Ethiopia (N = 487) Discussion The Ethiopian national malaria guideline requires species-specific diagnosis for the treatment of malaria [18], in all malarious areas at all levels of the care tier system. The conventional means, RDTs and microscopy, have different performances and operability. In settings like Ethiopia, health posts are the primary point-of-care for uncomplicated malaria, which is the most common presentation of the disease in routine care, and RDTs play a significant role in guiding targeted antimalarial treatment [18]. This study evaluated the performance of the point-of-care species-specific diagnostic BIOCREDIT Ag Pf/Pv (pLDH/pLDH) RDT compared with microscopy among self-reported cases in Ethiopia. Both tests were conducted by facility laboratory staff. The RDTs’ sensitivity for P. falciparum (87.9%) and P. vivax (86.7%), together with consistently high specificities, indicate better diagnostic performance than microscopy under routine point-of-care conditions, with microscopy sensitivities of 55.0% and 60.0%, respectively. The high PPV and NPV further support the reliability of the BIOCREDIT Ag Pf/Pv (pLDH/pLDH) RDT for routine clinical use. Overall, the BIOCREDIT Ag Pf/Pv (pLDH/pLDH) RDT outperformed facility microscopy across metrics, including sensitivity, agreement with qPCR, and area under the ROC curve (AUC ≥ 0.92) for both species. These findings have important operational implications for malaria diagnosis in Ethiopia, particularly following the country’s strategy for accessible diagnosis and treatment [1]. The occurrence of discordant results (50 false negatives and 30 false positives relative to qPCR) warrants consideration. False-negative RDT results in this study were primarily associated with low parasite densities. Conversely, false-positive RDT results may be explained by the cross-reactivity with non-target species [19, 20] and the degradation of parasite DNA from DBS during sample collection and transport can lead to reduced sensitivity or inconsistent amplification in 18S rRNA qPCR assays [21, 22]. Our findings are consistent with prior evidence that pLDH-based RDTs can compensate for limitations of HRP2-based tests and improve species-specific detection in settings where pfhrp2/3 deletion requires a replacement [10, 23, 24]. Such deletions have been increasingly documented in Ethiopia, including the present study regions [24–28]. The strong performance observed suggests that targeting the LDH antigen provides a reliable diagnostic alternative in regions where hrp2/3-deletion strains are circulating. The more rapid antigen clearance after treatment improves the specificity in routine clinical settings. The observed superior performance of the BIOCREDIT Ag Pf/Pv (pLDH/pLDH) RDT over microscopy is consistent with other field evaluations in Ethiopia and other settings [29–31]. These studies showed that BIOCREDIT Ag Pf/Pv (pLDH/pLDH) RDTs can match or exceed routine microscopy performance. In addition, the BIOCREDIT Ag Pf/Pv (pLDH/pLDH) RDT has been shown to have an improved analytical sensitivity for P. falciparum and P. vivax LDH compared to other WHO Pre-Qualified malaria RDTs [7]. This may partly explain the higher clinical sensitivity observed in the present study. As one of the first field evaluations following Ethiopia’s transition from HRP2-based diagnostics, the strong agreement with qPCR (κ = 0.92) indicates that this assay can serve as a practical and reliable point-of-care alternative. The performance difference in microscopy in the different studies could be related to the quality of supplies and experience of laboratory personnel, and the inconsistency of supportive supervision and quality control [4, 5, 8, 29–31]. The strong kappa agreement of the RDT with qPCR in this study underscores that, with basic training and aided by the manufacturer’s procedure, the BIOCREDIT Ag Pf/Pv (pLDH/pLDH) assay provides reliable point-of-care diagnostic performance that corroborates previous observations [32, 33]. Both microscopy and the BIOCREDIT Ag Pf/Pv (pLDH/pLDH) RDT performance improved as parasite density increased, consistent with previous reports [8, 13, 29, 32, 34]. For P. falciparum, the BIOCREDIT Ag Pf/Pv (pLDH/pLDH) RDT sensitivity rose from 67.4% at < 1,000 copies µL to 100% at both the 1,000–4,999 and ≥ 5,000 copies/µL strata. This underscores the limitation of pLDH-based RDTs in detecting low-density infections, as previously reported [8, 32]. While the dip in performance at lower parasitemia (< 1,000 copies/µL) highlights its limitation in asymptomatic surveillance, where infections often occur at submicroscopic densities [35], the rapid decay of the pLDH antigen provides a distinct advantage for elimination efforts. Therefore, while the BIOCREDIT RDT appears highly effective for routine clinical diagnosis of symptomatic patients, more sensitive tools may still be required for community-based surveillance and active case detection in elimination settings. In contrast, facility microscopy showed relatively higher sensitivity than RDTs in the low-density range (78.5%), underscoring the value of routine microscopy in identifying infections that may be missed by these RDTs. Although sensitivity for facility microscopy increased at intermediate and higher densities, the improvement was modest compared to the substantial jump observed for the RDT. A similar trend was observed for P. vivax. The BIOCREDIT Ag Pf/Pv (pLDH/pLDH) RDT exhibited a substantial increase in sensitivity from 68.2% (at < 1,000 copies/μL) to 98.4% (1,000–4,999 copies/µL), with the facility microscopy again showing relatively better sensitivity (72.0%) at low density (< 1,000 copies/μL), which increased to 100% at ≥ 5,000 copies/μL, with relatively lower performance at intermediate densities (1,000–4,999 copies/μL). This is consistent with known performance challenges of pLDH assays for P. vivax [36, 37]. Collectively, this reinforces the necessity of maintaining high-quality microscopy capabilities, especially in elimination-focused programs where low-density infections are of major epidemiological importance [13, 29]. Due to the small number of mixed infections, density-stratified analysis was not performed. The added advantage of BIOCREDIT Ag Pf/Pv (pLDH/pLDH) RDT in detecting a substantial proportion of moderate to high density infections suggests its adequate analytical sensitivity for most clinically relevant infections, encountered at the primary care level in our study. Geographic differences in the co-endemicity level (e.g., P. vivax being relatively more common in South Ethiopia) were consistent with previous observations [38–41], while mixed infections are more frequent in the southern parts of the country [42, 43]. These co-endemicities underscore the need for species-specific diagnosis to guide appropriate case management and scale in line with the elimination efforts. Moreover, operationally, the observed high specificity of the RDT (≥ 97%) reduces the risk of overtreatment due to false positives, which is important for preserving antimalarial drug effectiveness and avoiding unnecessary drug exposure [44]. For most clinically important parasitemia levels, BIOCREDIT Ag Pf/Pv (pLDH/pLDH) RDT demonstrates a clear advantage over microscopy, including in detecting mixed infections confirmed by qPCR. This highlights its utility both as an alternative tool in settings with limited microscopy access and/or as a complementary point-of-care test that enhances routine case detection, in settings like Ethiopia that require species-specific diagnosis and treatment [18]. From a policy perspective, our findings support Ethiopia’s national shift to non-HRP2-based RDTs and provide empirical evidence that WHO-prequalified BIOCREDIT Ag Pf/Pv (pLDH/pLDH) RDTs can maintain high species-specific diagnostic performance at point-of-care conditions. Strengths of the study include the relatively large sample size (planned to provide ≥ 80% power to detect a 10% sensitivity difference between RDT and microscopy), across two epidemiologically distinct regions, prospective point-of-care testing by routine health workers (reflecting point-of-care performance), which increases confidence that findings apply to primary care settings in Ethiopia and similar co-endemic regions. However, operational factors (single RDT lot used, local storage and temperature conditions, and operator variability) could affect generalizability; while we trained facility staff, existing programmatic performance across different lots and broader health system conditions may vary. Conclusions The BIOCREDIT Ag Pf/Pv (pLDH/pLDH) RDT demonstrated better diagnostic accuracy at moderate (18S qPCR 1,000–4,999 copies/μL) and above parasite densities for both P. falciparum and P. vivax in the routine point-of-care setting in two Ethiopian regions with co-endemic transmission. While routine microscopy performed slightly better at low (18S qPCR < 1,000 copies/μL) parasite densities. RDT showed higher overall sensitivity at moderate parasitemia for both P. falciparum and P. vivax. In addition, it picked up infections missed by microscopy, identified additional mixed infections, and exhibited stronger concordance with the 18S qPCR. These results underscore the feasibility of routine point-of-care use of the BIOCREDIT Ag Pf/Pv (pLDH/pLDH RDT) at the primary care level in Ethiopia as a sensitive and specific tool. Supplementary Information Additional file 1. Acknowledgements We thank the study participants, staff at Village 8/9 and Beto HCs, and AHRI laboratory personnel for their support. We acknowledge Unitaid for funding, PATH (sponsor), and AHRI (implementing partner) for coordination. Abbreviations Area under the curve Armauer Hansen research institute Confidence interval Deoxyribonucleic acid Dried blood spots Health center Histidine-rich protein 2 Interquartile range Negative predictive value Plasmodium lactate dehydrogenase Positive predictive value Quantitative polymerase chain reaction Rapid diagnostic test Receiver operating characteristic Research Electronic Data Capture Author contributions GJD and EG designed the study. SD, EGG, GJD, and EG reviewed the protocol. EF, ZB, and EM, involved in the laboratory work. EM, FAK, ME, and TN contributed to data management and statistical analysis. EM, EF, ZB, FAK, MGT, TN, ME, MM, MS, DL, SF, MU, DBD, AF, MF, AB, SP, DHY, EGG, SD, GJD, and EG contributed to drafting and revising the manuscript. All authors read and approved the final manuscript. Funding The study was funded by Unitaid, Global Health Campus, Chemin de Pommier 40, 5th Floor, 1218 Grand-Saconnex, Switzerland. The funder had no role in study design, data collection, analysis, or manuscript preparation. Data availability All data generated or analyzed during this study are available from the corresponding author upon reasonable request. Declarations Ethics approval and consent to participate The main study protocol, as well as the protocol for this ancillary study, was reviewed and approved by the Armauer Hansen Research Institute and All Africa Leprosy Rehabilitation and Training Center Ethics Review Committee (Protocol number: PO-59–22), the National Research Ethics Review Committee (NRERC, Reference number: 17/256/695/23), the Ethiopian Food and Drug Authority (EFDA, Unique ID number: ET-CT-0038), and the WHO Ethics Review Committee (Protocol ID: ERC.0003842). Before sample collection, informed written consent and/or assent were obtained from all participants and/or the parents/guardians of the children. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Additional file 1. Data Availability Statement All data generated or analyzed during this study are available from the corresponding author upon reasonable request.